AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31021404 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosistos protocol (P-PDT)
Number of subjects: 46
Study 31021404 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (C-PDT)
Number of subjects: 46
Study 31006996 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CCT) group
Number of subjects: 959
Study 31006996 — intervention group
Group type: COMPARATOR
Intervention: Non-CCT group
Number of subjects: 959
Study 29113968 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac (NSAID)
Number of subjects: 253
Study 29113968 — intervention group
Group type: COMPARATOR
Intervention: norfloxacin (antibiotic)
Number of subjects: 253
Study 26116627 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 mg titrated to 25 mg)
Number of subjects: 17
Study 26116627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23963306 — intervention group
Group type: EXPERIMENTAL
Intervention: mARble (mobile Augmented Reality learning)
Number of subjects: 10
Study 23963306 — intervention group
Group type: COMPARATOR
Intervention: Textbook learning (control group)
Number of subjects: 10
Study 21457929 — intervention group
Group type: COMPARATOR
Intervention: Standard-fluence photodynamic therapy (PDT) at 50 J/cm²
Number of subjects: 42
Study 21457929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence photodynamic therapy (PDT) at 25 J/cm²
Number of subjects: 42
Study 21457929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Standard-fluence and Low-fluence PDT)
Number of subjects: 42
Study 19344725 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intranasal dose of oxytocin
Number of subjects: 0
Study 19344725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 17893153 — intervention group
Group type: EXPERIMENTAL
Intervention: Altastaph (200 mg/kg in two infusions 24 hours apart)
Number of subjects: 40
Study 17893153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17893153 — intervention group
Group type: EXPERIMENTAL
Intervention: Altastaph
Number of subjects: 40
Study 15761542 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PD) 2.4-3.5 mg/m2 BSA
Number of subjects: 44
Study 15761542 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) 10-15 mg/m2 BSA
Number of subjects: 44
Study 11479392 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 118
Study 11479392 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg three times daily
Number of subjects: 118
Study 9755269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspeculum collection method
Number of subjects: 686
Study 9755269 — intervention group
Group type: COMPARATOR
Intervention: Speculum collection method
Number of subjects: 686
Study 7923254 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRD patients
Number of subjects: 30
Study 7923254 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRD + LVD patients
Number of subjects: 30
Study 7923254 — intervention group
Group type: EXPERIMENTAL
Intervention: LVD patients
Number of subjects: 30
Study 7923254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 30
Study 7923254 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip response
Number of subjects: 30
Study 7923254 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study 2457422 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and methotrexate, alternating after four cycles with cyclophosphamide, lomustine, vincristine, and methotrexate + irradiation at 40 Gy
Number of subjects: 133
Study 2457422 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and methotrexate, alternating after four cycles with cyclophosphamide, lomustine, vincristine, and methotrexate
Number of subjects: 133
Study 4808813 — intervention group
Group type: EXPERIMENTAL
Intervention: Erect position
Number of subjects: 20
Study 4808813 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 20
Study 31841830 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based concept mapping education
Number of subjects: 201
Study 31841830 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving web-based concept mapping education)
Number of subjects: 201
Study 30406858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Number of subjects: 0
Study 28407727 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI‐nf from the amygdala (N=19)
Number of subjects: 36
Study 28407727 — intervention group
Group type: COMPARATOR
Intervention: Control group (rtfMRI‐nf from a parietal region, N=17)
Number of subjects: 36
Study 25854013 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene (group A)
Number of subjects: 120
Study 25854013 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture-moxibustion + Chinese medicine (group B)
Number of subjects: 120
Study 25854013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene + acupuncture-moxibustion + Chinese medicine (group C)
Number of subjects: 120
Study 24058684 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg(‐1) of body weight)
Number of subjects: 8
Study 24058684 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (PLA)
Number of subjects: 8
Study 21043788 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartRx Web program (intervention)
Number of subjects: 346
Study 21043788 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 346
Study 19268900 — intervention group
Group type: EXPERIMENTAL
Intervention: MammoSite brachytherapy (34 Gy in 3.4-Gy fractions)
Number of subjects: 1440
Study 16776407 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine plain
Number of subjects: 1391
Study 16776407 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine
Number of subjects: 1391
Study 16776407 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine plain
Number of subjects: 1391
Study 16776407 — intervention group
Group type: COMPARATOR
Intervention: Articaine with epinephrine
Number of subjects: 1391
Study 15307698 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyan Zhixue Capsule (XYZXC)
Number of subjects: 0
Study 15307698 — intervention group
Group type: COMPARATOR
Intervention: Adrenosoem (AC‐17)
Number of subjects: 0
Study 15307698 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study 11267952 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1430
Study 11267952 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 1430
Study 9259359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride pills (60 mEq of sodium per day)
Number of subjects: 20
Study 9259359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8481365 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (70 mg/m2)
Number of subjects: 87
Study 8481365 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (70 mg/m2)
Number of subjects: 87
Study 8481365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone (14 mg/m2)
Number of subjects: 87
Study 8481365 — intervention group
Group type: COMPARATOR
Intervention: All agents
Number of subjects: 87
Study 8481365 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin or Epirubicin
Number of subjects: 87
Study 8481365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone
Number of subjects: 87
Study 3102153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat
Number of subjects: 12
Study 3102153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein
Number of subjects: 12
Study 3102153 — intervention group
Group type: COMPARATOR
Intervention: Insulin‐induced hypoglycaemia
Number of subjects: 12
Study 3102153 — intervention group
Group type: COMPARATOR
Intervention: Intravenous arginine
Number of subjects: 12
Study 3102153 — intervention group
Group type: COMPARATOR
Intervention: Oral carbohydrate
Number of subjects: 12
Study 3102153 — intervention group
Group type: COMPARATOR
Intervention: Control days
Number of subjects: 12
Study 28888220 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg immediate-release co-crystal of tramadol-celecoxib (CTC)
Number of subjects: 30
Study 28888220 — intervention group
Group type: COMPARATOR
Intervention: 100 mg immediate-release tramadol
Number of subjects: 30
Study 28888220 — intervention group
Group type: COMPARATOR
Intervention: 100 mg celecoxib
Number of subjects: 30
Study 28888220 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg immediate-release tramadol and 100 mg celecoxib
Number of subjects: 30
Study 27159349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate
Number of subjects: 25
Study 25183978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent subglottic secretion drainage (SSD)
Number of subjects: 76
Study 25183978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SSD)
Number of subjects: 76
Study 22542983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 70
Study 22542983 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 70
Study 20868506 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, low fat diet
Number of subjects: 108
Study 20868506 — intervention group
Group type: COMPARATOR
Intervention: Moderate carbohydrate, increased protein diet
Number of subjects: 108
Study 19031222 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (rhCG)
Number of subjects: 125
Study 19031222 — intervention group
Group type: COMPARATOR
Intervention: urinary human chorionic gonadotropin (uhCG)
Number of subjects: 125
Study 16308443 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaferon LB (5 mg/ml - 3 ml daily inhalations)
Number of subjects: 43
Study 16308443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert solution)
Number of subjects: 43
Study 12531809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/m(2)/d for 28 days in induction, plus taper)
Number of subjects: 1000
Study 12531809 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (40 mg/m(2)/d)
Number of subjects: 1000
Study 12531809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1000
Study 12531809 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 1000
Study 12531809 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 6-mercaptopurine
Number of subjects: 1000
Study 12531809 — intervention group
Group type: COMPARATOR
Intervention: Oral 6-mercaptopurine
Number of subjects: 1000
Study 14610016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1703
Study 14610016 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1703
Study 14610016 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (no abciximab)
Number of subjects: 1703
Study 9440388 — intervention group
Group type: EXPERIMENTAL
Intervention: High-RS diet (amylomaize starch, 55.2 +/- 3.5 g RS/d)
Number of subjects: 12
Study 9440388 — intervention group
Group type: COMPARATOR
Intervention: Low-RS diet (available cornstarch, 7.7 +/- 0.3 g RS/d)
Number of subjects: 12
Study 8591965 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenephrectomy therapy
Number of subjects: 0
Study 2693404 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch
Number of subjects: 18
Study 2693404 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 18
Study 892242 — intervention group
Group type: EXPERIMENTAL
Intervention: Early contact group (45 minutes of private skin to skin contact immediately after birth)
Number of subjects: 60
Study 892242 — intervention group
Group type: COMPARATOR
Intervention: Delayed contact group (45 minutes of private skin to skin contact 12 hours after birth)
Number of subjects: 60
Study 892242 — intervention group
Group type: COMPARATOR
Intervention: Control group (no period of skin to skin contact)
Number of subjects: 60
Study 30790528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical intervention to increase a woman's sense of control of her life before behavioral weight loss efforts
Number of subjects: 0
Study 28216412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT; 40min; 4×4 intervals 90% peak heart rate)
Number of subjects: 28
Study 28216412 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT; 47min 70% HRpeak)
Number of subjects: 28
Study 28216412 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Continuous Training (LICT; 47min 50% HRpeak)
Number of subjects: 28
Study 28216412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 28216412 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28
Study 24619945 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated, humidified high-flow nasal cannula (HHHFNC)
Number of subjects: 76
Study 24619945 — intervention group
Group type: COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 76
Study 23455033 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab and heparin
Number of subjects: 1721
Study 23455033 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 1721
Study 21796128 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 58
Study 21796128 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 58
Study 19587440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo (4 capsules once, 3 times per day)
Number of subjects: 39
Study 19587440 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 39
Study 16709464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 4mg
Number of subjects: 829
Study 16709464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Number of subjects: 829
Study 16709464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study 15290731 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 671
Study 11778566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dose of 25.2‐30.6 Gy
Number of subjects: 51
Study 11778566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCI)
Number of subjects: 51
Study 11778566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 51
Study 9298332 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 25
Study 9298332 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 25
Study 9298332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9298332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.25 g/kg)
Number of subjects: 25
Study 9298332 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 25
Study 8333931 — intervention group
Group type: EXPERIMENTAL
Intervention: New non-preserved artificial tear (sodium chloride 0.34% W/W, hydroxyethylcellulose 0.44% W/W)
Number of subjects: 30
Study 8333931 — intervention group
Group type: COMPARATOR
Intervention: Other tear substitutes
Number of subjects: 30
Study 28528536 — intervention group
Group type: EXPERIMENTAL
Intervention: R+D (10 mL of 0.25% ropivacaine + 0.5μg/kg dexmedetomidine)
Number of subjects: 60
Study 28528536 — intervention group
Group type: COMPARATOR
Intervention: R (10 mL of 0.25% ropivacaine)
Number of subjects: 60
Study 27224446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (ASA) 100mg per day
Number of subjects: 22
Study 27224446 — intervention group
Group type: COMPARATOR
Intervention: Oral aspirin (ASA) 100mg per day via gastric tube
Number of subjects: 22
Study 27224446 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to aspirin (both IV and oral)
Number of subjects: 22
Study 25222173 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline Perceived Vulnerability (PV)
Number of subjects: 267
Study 25222173 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in Perceived Vulnerability (PV) from baseline to end of treatment
Number of subjects: 267
Study 22492823 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dilution HDF
Number of subjects: 14
Study 22492823 — intervention group
Group type: COMPARATOR
Intervention: Mid-dilution HDF
Number of subjects: 14
Study 20298539 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion within six hours
Number of subjects: 190
Study 20298539 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 190
Study 20298539 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Number of subjects: 190
Study 18630539 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at single acupoint
Number of subjects: 52
Study 15830898 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem behavior prevention program
Number of subjects: 2453
Study 15830898 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2453
Study 12612946 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1513
Study 12612946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 10390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (141W94) 150 mg
Number of subjects: 12
Study 10390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (141W94) 300 mg
Number of subjects: 12
Study 10390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (141W94) 600 mg
Number of subjects: 12
Study 10390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (141W94) 900 mg
Number of subjects: 12
Study 10390223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir (141W94) 1200 mg
Number of subjects: 12
Study 10390223 — intervention group
Group type: COMPARATOR
Intervention: Soft gelatin capsule of amprenavir
Number of subjects: 12
Study 8708505 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens containing ofloxacin and rifampicin
Number of subjects: 60
Study 8708505 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens containing rifampicin
Number of subjects: 60
Study 8708505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin and rifampicin
Number of subjects: 60
Study 8708505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin added to WHO recommended M.B.-MDT regimen
Number of subjects: 60
Study 8708505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 60
Study 1675881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 496
Study 1675881 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin + Metronidazole
Number of subjects: 496
Study 6309528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 30
Study 30909690 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea after drinking
Number of subjects: 417
Study 30909690 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea after drinking in heavy drinkers
Number of subjects: 417
Study 29717574 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 240
Study 29717574 — intervention group
Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 240
Study 27297937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohydroxyapatite group (NHA)
Number of subjects: 27
Study 27297937 — intervention group
Group type: COMPARATOR
Intervention: Pure graft group
Number of subjects: 27
Study 25276591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin administered by traditional birth attendants (TBAs)
Number of subjects: 1889
Study 25276591 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a rural health center facilitated by TBAs
Number of subjects: 1889
Study 25276591 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral and/or initiation of antibiotics
Number of subjects: 1889
Study 25276591 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgment of 'extremely sick' by TBAs
Number of subjects: 1889
Study 22817122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (SH)
Number of subjects: 42
Study 22817122 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate (LC)
Number of subjects: 42
Study 20136474 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) applied to supraspinatus and posterior deltoid muscles
Number of subjects: 50
Study 20136474 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation methods
Number of subjects: 50
Study 17635310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-dense formula (NDF)
Number of subjects: 49
Study 17635310 — intervention group
Group type: COMPARATOR
Intervention: Energy-supplemented formula (ESF)
Number of subjects: 49
Study 16298721 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Number of subjects: 600
Study 16298721 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 600
Study 11974558 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol/levonorgestrel 50/10 micrograms/24 h patch
Number of subjects: 468
Study 11974558 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol/levonorgestrel 75/15 micrograms/24 h patch
Number of subjects: 468
Study 11974558 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol/levonorgestrel 100/20 micrograms/24 h patch
Number of subjects: 468
Study 9784666 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment in iron-depleted patients
Number of subjects: 70
Study 9784666 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (iron-replete patients)
Number of subjects: 70
Study 9784666 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-depleted patients
Number of subjects: 70